Skip Navigation


Rheumatology Advance Access originally published online on June 24, 2007
Rheumatology 2007 46(10):1520-1524; doi:10.1093/rheumatology/kem147
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
46/10/1520    most recent
kem147v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hider, S. L.
Right arrow Articles by Thomson, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hider, S. L.
Right arrow Articles by Thomson, W.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

REVIEWS

The pharmacogenetics of methotrexate

S. L. Hider, I. N. Bruce and W. Thomson

arc Epidemiology Unit, University of Manchester, UK.

Correspondence to: Dr I. N. Bruce, arc Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT UK. E-mail: ian.bruce{at}manchester.ac.uk


  Abstract

Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately. Pharmacogenetics is the study of variability in drug response due to heredity. MTX has a complex intracellular metabolism and acts via a number of key enzymes. This review critically appraises the studies of MTX pharmacogenetics and highlights the need for further work in this area.

KEY WORDS: Rheumatoid arthritis, MTX, Pharmacogenetics

Submitted 12 February 2007; revised version accepted 16 April 2007.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. M. van der Kooij, J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar
Comment on: The pharmacogenetics of methotrexate
Rheumatology, April 1, 2008; 47(4): 557 - 557.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.